Prophylactic oophorectomy in women at increased cancer risk
Prophylactic oophorectomy in women at increased cancer risk
复制标题
DOI：
10.1097/gco.0b013e32801195da
复制
发表时间：
2007-02-01
影响因子：
2.1
通讯作者：
Rebbeck, Timothy R.
中科院分区：
文献类型：
--
作者：
Domchek, Susan M.;Rebbeck, Timothy R.
双侧预防性输卵管卵巢切除术被广泛用于降低BRCA 1/2突变妇女的癌症风险。双侧预防性输卵管卵巢切除术可显著降低乳腺癌风险约50%，卵巢癌风险80-95%，但可能伴有绝经期症状，生活质量受损和加速骨质流失。因此，必须仔细考虑关于双侧预防性输卵管卵巢切除术的时机和双侧预防性输卵管卵巢切除术后激素替代疗法的使用的决定。最近的发现在过去的一年中，研究进一步检查了与双侧预防性输卵管卵巢切除术相关的生活质量相关的问题，并证明双侧预防性输卵管卵巢切除术后的激素替代疗法，未受影响妇女的卵巢切除术并不否定双侧预防性输卵管卵巢切除术提供的乳腺癌风险降低。研究提供了额外的信息，对癌症的剩余风险后，双侧预防性输卵管卵巢切除术已证明其效益林奇综合征，并提出了短期死亡率效益后，双侧预防性输卵管卵巢切除术BRCA 1/2突变携带者。卵巢切除术及其对癌症风险增加的妇女的临床管理的影响。
Purpose of reviewBilateral prophylactic salpingo-oophorectomy is widely used for cancer risk reduction in women with BRCA1/2 mutations. Bilateral prophylactic salpingo-oophorectomy significantly reduces breast cancer risk by approximately 50% and ovarian cancer risk by 80-95% but maybe accompanied by menopausal symptoms impaired quality of life and accelerated bone loss. therefore decisions regarding the timing of bilateral prophylactic salpingo-oophorectomy and the use of post-bilateral prophylactic salpingo-oophorectomy hormone replacement therapy must be carefully considered.Recent findingsOver the last year, studies have further examined issues related to quality of life associated with bilateral prophylactic salpingo-oophorectomy and have demonstrated that hormone replacement therapy following bilateral prophylactic salpingo-oophorectomy in unaffected women does not negate the breast cancer risk reduction that bilateral prophylactic salpingo-oophorectomy provides. Studies have provided additional information on the residual risk of cancer following bilateral prophylactic salpingo-oophorectomy have demonstrated its benefit in Lynch syndrome and have suggested a short-term mortality benefit following bilateral prophylactic salpingo-oophorectomy in BRCA1/2 mutation carriers.SummaryWe review the recent studies regarding bilateral prophylactic salpingo-oophorectomy and their implications for the clinical management of women who are at increased cancer risk.